Analyst Confidence Soars for 89bio Despite Lengthy Clinical Pathway
While 89bio continues to advance its key Phase 3 trial for its flagship drug candidate, Pegozafermin, the company has received ...
© 2024 Stocks Today
Tag: 89bio
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Institutional Investors Rally Behind GXO Logistics